J C LaRosa

Summary

Affiliation: State University of New York
Country: USA

Publications

  1. ncbi request reprint Understanding risk in hypercholesterolemia
    John C LaRosa
    State University of New York Downstate Medical Center, Brooklyn, New York 11203, USA
    Clin Cardiol 26:I3-6. 2003
  2. ncbi request reprint Low-density lipoprotein cholesterol reduction: the end is more important than the means
    John C LaRosa
    SUNY Downstate Medical Center, Brooklyn, New York, USA
    Am J Cardiol 100:240-2. 2007
  3. ncbi request reprint Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)
    John C LaRosa
    State University of New York Health Science Center, New York, New York, USA
    Am J Cardiol 100:747-52. 2007
  4. doi request reprint Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events
    John C LaRosa
    State University of New York Health Science Center, New York, NY, USA
    Am J Cardiol 111:1221-9. 2013
  5. ncbi request reprint Cardiovascular risk factors in minorities
    John C LaRosa
    Office of the President, SUNY Downstate Medical Center, Brooklyn, NY 11203 2098, USA
    Am J Med 118:1314-22. 2005
  6. ncbi request reprint Reduction of serum LDL-C levels: a relationship to clinical benefits
    John C LaRosa
    University of New York Health Center at Brooklyn, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA
    Am J Cardiovasc Drugs 3:271-81. 2003
  7. ncbi request reprint New and emerging data from clinical trials of statins
    John C LaRosa
    State University of New York Downstate Medical Center, 450 Clarkson Avenue, Box 1, Brooklyn, NY 11203 2098, USA
    Curr Atheroscler Rep 6:12-9. 2004
  8. ncbi request reprint Evidence-based management of dyslipidemias in women
    John C LaRosa
    The State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    Curr Atheroscler Rep 5:379-85. 2003
  9. ncbi request reprint What do the statins tell us?
    John C LaRosa
    State University of New York Health Science Center at Brooklyn, Brooklyn, NY 11203, USA
    Am Heart J 144:S21-6. 2002
  10. ncbi request reprint Outcomes of lipid-lowering treatment in postmenopausal women
    John C LaRosa
    State University of New York Health Science Center at Brooklyn, 11203, USA
    Drugs Aging 19:595-604. 2002

Detail Information

Publications31

  1. ncbi request reprint Understanding risk in hypercholesterolemia
    John C LaRosa
    State University of New York Downstate Medical Center, Brooklyn, New York 11203, USA
    Clin Cardiol 26:I3-6. 2003
    ..With the availability of statin therapy, we are now able to reduce the risk of major adverse CHD events by an average of 30%, regardless of patient age or gender...
  2. ncbi request reprint Low-density lipoprotein cholesterol reduction: the end is more important than the means
    John C LaRosa
    SUNY Downstate Medical Center, Brooklyn, New York, USA
    Am J Cardiol 100:240-2. 2007
    ....
  3. ncbi request reprint Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)
    John C LaRosa
    State University of New York Health Science Center, New York, New York, USA
    Am J Cardiol 100:747-52. 2007
    ....
  4. doi request reprint Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events
    John C LaRosa
    State University of New York Health Science Center, New York, NY, USA
    Am J Cardiol 111:1221-9. 2013
    ..In conclusion, clinical trial evidence demonstrating the efficacy and safety of LDL cholesterol lowering to a very low level is essential to ascertain the benefits and risks in reducing the residual risk of vascular disease...
  5. ncbi request reprint Cardiovascular risk factors in minorities
    John C LaRosa
    Office of the President, SUNY Downstate Medical Center, Brooklyn, NY 11203 2098, USA
    Am J Med 118:1314-22. 2005
    ..Risk factor intervention should be pursued in minority groups but with the understanding that clinical trials have not ruled out the possibility of qualitative or quantitative differences in response rates among different groups...
  6. ncbi request reprint Reduction of serum LDL-C levels: a relationship to clinical benefits
    John C LaRosa
    University of New York Health Center at Brooklyn, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA
    Am J Cardiovasc Drugs 3:271-81. 2003
    ..More potent agents in development are likely to make such levels more readily achievable, as well as making guideline targets attainable for many of the large number of patients who currently fail to reach them...
  7. ncbi request reprint New and emerging data from clinical trials of statins
    John C LaRosa
    State University of New York Downstate Medical Center, 450 Clarkson Avenue, Box 1, Brooklyn, NY 11203 2098, USA
    Curr Atheroscler Rep 6:12-9. 2004
    ....
  8. ncbi request reprint Evidence-based management of dyslipidemias in women
    John C LaRosa
    The State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    Curr Atheroscler Rep 5:379-85. 2003
  9. ncbi request reprint What do the statins tell us?
    John C LaRosa
    State University of New York Health Science Center at Brooklyn, Brooklyn, NY 11203, USA
    Am Heart J 144:S21-6. 2002
    ....
  10. ncbi request reprint Outcomes of lipid-lowering treatment in postmenopausal women
    John C LaRosa
    State University of New York Health Science Center at Brooklyn, 11203, USA
    Drugs Aging 19:595-604. 2002
    ..Therapy for lipoprotein disorders in women and men is identical. For the overwhelming majority of patients, treatment with statin therapy is both highly efficacious and well tolerated...
  11. doi request reprint Highlighting the unmet need for prevention: an epidemiologic perspective
    John C LaRosa
    State University of New York, Downstate Medical Center in Brooklyn, NY, USA
    Postgrad Med 112:6-11. 2002
    ..Urbanization, the trend toward a more sedentary lifestyle, and the abandonment of a vegetarian-based diet are among the premier underlying causes of ischemic heart disease today...
  12. doi request reprint Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial)
    John C LaRosa
    State University of New York, Health Science Center, Brooklyn, New York, USA
    Am J Cardiol 105:283-7. 2010
    ..In TNT, analyses limited to the primary end point significantly underestimated the decrease in total cardiovascular disease burden achieved by intensive low-density lipoprotein cholesterol lowering...
  13. ncbi request reprint Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    John C LaRosa
    State University of New York Health Science Center, Brooklyn, NY 11203, USA
    N Engl J Med 352:1425-35. 2005
    ..We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable coronary heart disease (CHD)...
  14. ncbi request reprint The benefits of statin therapy--what questions remain?
    Antonio M Gotto
    Weill Medical College of Cornell University, Olin Hall, Room 205, 445 East 69th Street, New York, NY 10021, USA
    Clin Cardiol 28:499-503. 2005
    ..Early trials provided a solid foundation of knowledge on the efficacy and safety of statins. Recent and ongoing trials generate new data to resolve remaining questions in the fields of CHD prevention and lipidology...
  15. ncbi request reprint Prevention and treatment of coronary heart disease: who benefits?
    J C LaRosa
    State University of New York Downstate Medical Center, Brooklyn, New York, USA
    Circulation 104:1688-92. 2001
    ..Several ongoing trials may resolve the controversies about which patient groups will benefit from different prevention and treatment strategies...
  16. ncbi request reprint Is aggressive lipid-lowering effective and safe in the older adult?
    John C LaRosa
    State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
    Clin Cardiol 28:404-7. 2005
    ..This paper reviews the benefits of statin therapy in the elderly and discusses the reality versus the perception of risk, selection of appropriate patients, and ways in which any risks that may exist can be minimized further...
  17. ncbi request reprint Primary prevention: the unsettling question
    John C LaRosa
    SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    Curr Atheroscler Rep 7:1-2. 2005
  18. ncbi request reprint Use of statin drugs in women
    John C LaRosa
    State University of New York, Downstate Medical Center, Brooklyn, New York, USA
    J Hypertens Suppl 20:S70-2. 2002
    ..Patients at risk should receive cholesterol-lowering treatment with statin drugs to prevent both atherosclerotic morbidity and mortality...
  19. ncbi request reprint Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials
    J C LaRosa
    Office of the President, State University of New York Health Science Center at Brooklyn, 11203, USA
    JAMA 282:2340-6. 1999
    ..Lowering low-density lipoprotein cholesterol (LDL-C) is known to reduce risk of recurrent coronary heart disease in middle-aged men. However, this effect has been uncertain in elderly people and women...
  20. ncbi request reprint Past, present, and future standards for management of dyslipidemia
    John C LaRosa
    State University of New York Health Science Center, Brooklyn, New York 11203, USA
    Am J Med 116:3S-8S. 2004
    ....
  21. ncbi request reprint Chemoprevention of coronary atherosclerosis: the role of lipid interventions. A position paper of the American Council on Science and Health
    John C LaRosa
    State University of New York Health Science Center at Brooklyn, NY, USA
    MedGenMed 4:12. 2002
    ..Although more difficult to prove, earlier intervention can almost surely lower the risk of later, potentially lethal, coronary events...
  22. ncbi request reprint Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study
    David D Waters
    University of California, San Francisco, California, USA
    J Am Coll Cardiol 48:1793-9. 2006
    ..We sought to assess the effects on cerebrovascular events of treating patients with stable coronary disease with low-density lipoprotein cholesterol (LDL-C) levels substantially below 100 mg/dl...
  23. ncbi request reprint Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
    Prakash Deedwania
    Veterans Affairs Central California Healthcare System and University of California San Francisco School of Medicine, San Francisco, CA, USA
    Lancet 368:919-28. 2006
    ....
  24. ncbi request reprint HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
    Philip Barter
    Heart Research Institute, Sydney, Australia
    N Engl J Med 357:1301-10. 2007
    ..High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol...
  25. ncbi request reprint The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study
    John B Kostis
    University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903 0019, USA
    J Clin Hypertens (Greenwich) 10:367-76. 2008
    ..The effect of lower SBP on stroke was most pronounced in the lowest LDL-C tertile...
  26. doi request reprint Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery
    Sanjiv J Shah
    Division of Cardiology, San Francisco General Hospital, University of California, San Francisco, California 94110, USA
    J Am Coll Cardiol 51:1938-43. 2008
    ....
  27. doi request reprint Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
    John J P Kastelein
    Academic Medical Center, Department of Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands
    Circulation 117:3002-9. 2008
    ....
  28. ncbi request reprint Justifying lipid-lowering therapy in persons >/=65 years of age
    John C LaRosa
    Am J Cardiol 90:1330-2. 2002
  29. ncbi request reprint Means and ends of statins and low-density lipoprotein cholesterol lowering
    John C LaRosa
    J Am Coll Cardiol 50:419-20. 2007
  30. ncbi request reprint Cholesterol and coronary disease--the altered landscape
    John C LaRosa
    Cardiovasc Drugs Ther 18:9-10. 2004
  31. ncbi request reprint At the heart of the statin benefit
    John C LaRosa
    J Am Coll Cardiol 46:1863. 2005